rikki

rikki | Joined since 2013-08-10

Investing Experience -
Risk Profile -

Followers

1

Following

0

Blog Posts

2

Threads

2,020

Blogs

Threads

Portfolio

Follower

Following

Summary
Total comments
2,020
Past 30 days
1
Past 7 days
0
Today
0

User Comments
Stock

1 week ago | Report Abuse

Avaland @ 0.35 is one of the RHB Top 20 Small Cap Jewels 2024 launched 14/5/2024

Stock

2024-01-10 08:15 | Report Abuse

Deals of 2023: Best Initial Public Offering | Main Market
https://theedgemalaysia.com/node/695240

News & Blogs

2023-12-29 16:50 | Report Abuse

Mr Tan KW,

My Stock Pick for year 2024 :-

1) Hiaptek - 10 %
2) Kgb-wb - 10 %
3) Myeg - 10 %
4) Wcehb-wf - 30 %
5) Smrt - 30 %
6) Scgbhd-wa - 10 %

Thank you,
Rikki

News & Blogs

2022-12-30 21:07 | Report Abuse

My Picks for 2023 (I am No. 11 for year 2019)

1) Dnex 10 %
2) Gfm 10 %
3) Genetec 10 %
4) Infom 10 %
5) Itmax 10 %
6) Kobay 10 %
7) Opcom 10 %
8) Pccs 10 %
9) Pphb 10 %
10) Ptrb 10 %

Comments : i ) 50 % weightage in tech - expecting tech to rebound in 2nd Half 2023 (Dnex, Genetec, Infom, Itmax & Kobay ) ii) 30 % weightage in consumer - world including China are opening up after covid ; more demand for food (Ptrb), accommodation (Pphb) & sports activities (Pccs) & iii ) Gfm - Q3 turnover & profits big increases iv) Opcom - 5G, Optic Cables, Sarawak Jendela Projects & Eddie Ong effect )

Thank you

News & Blogs

2022-12-30 17:27 | Report Abuse

Mr Tan KW,

My Picks for 2023 (I am No. 11 for year 2019)

1) Dnex 10 %
2) Gfm 10 %
3) Genetec 10 %
4) Infom 10 %
5) Itmax 10 %
6) Kobay 10 %
7) Opcom 10 %
8) Pccs 10 %
9) Pphb 10 %
10) Ptrb 10 %

Thank you,
Rikki

Stock

2022-03-17 17:31 | Report Abuse

Rhone Ma Holdings Bhd (Fundamental BUY with TP RM1.07)
• Rhone Ma Holdings Bhd (Rhone Ma) is an end-to-end animal health solution provider. The company ventured into fresh milk production in 2019.
• Despite the slow business environment during the Covid-19 pandemic, Rhone Ma’s revenue has recorded a 12% CAGR over the past 2 years. In tandem with the expanding market revenue in Animal Health and Nutrition Industry, the company’s market share has grown from 4.7% in 2018 to 5.8% in 2021.
• Rhone Ma’s GMP compliant plant in Nilai which has a production capacity of 2,500 MT/year has commenced operation in April 2021. The plant is currently 35% utilised and is expected to increase gradually. Management guided the plant to reach full utilisation rate by end 2023 as the PJ GMP compliant plant has been running at full capacity (637 MT/year).
• Its Human Healthcare segment revenue grew 231% in 2021, attributed to the Covid-19 outbreak. The company’s CiTest Covid-19 Antigen Rapid Test Kit is widely used by clinics and hospitals. Moving forward, Rhone Ma will continue its R&D effort to expand its human healthcare products range such as other purpose test kit.
• We see Rhone Ma’s venturing into Ruminant industry as synergistic to its animal health product segment. Meanwhile, the government aims to increase the country’s fresh milk self-sufficiency level to 100% within five years; and this will create an opportunity to its 49% owned A2 Fresh SB. The company is planning to expand its dairy farm from 300 cattle to 500 cattle by end 2022, producing its own brand milk targeted to launch in 1Q2023.
• According to Protégé Associates, the Animal Health and Nutrition Industry has grown to a RM2.33bn revenue industry vs RM2.09bn in 2018. We see Rhone Ma is well positioned in the growing livestock market in Malaysia. BUY with a target price of RM1.07 based on 18x PER FY22F (3-year average).
• Financially, the company’s leverage is manageable with net gearing of less than 10%.

Rakuten Trade Research 17/3/2022

Stock

2022-03-01 15:32 | Report Abuse

Latest semiconductor players' results mostly in line, with 'buy in dip' opportunities seen
https://www.theedgemarkets.com/article/latest-semiconductor-players-results-mostly-line-buy-dip-opportunities-seen

Stock
Stock

2022-03-01 12:34 | Report Abuse

Ann Joo's earnings are expected to come off steeply due to lower steel average selling price (ASP) and rising costs.
https://www.klsescreener.com/v2/news/view/957689/ann-joo-s-margins-to-normalise-says-kenanga

Stock

2022-02-18 11:16 | Report Abuse

Anasuria Hibiscus

The segment achieved an EBITDA and a PBT of RM45.0 million and RM27.9 million respectively in the Current Quarter as compared to that achieved in the Preceding Quarter, i.e. an EBITDA of RM35.1 million and a PBT of RM18.6 million.

Source : Hibiscus Q2 Dec 2021 Report dd 17/2/2022

Stock

2022-02-17 11:15 | Report Abuse

On track for record earnings in 2022F - Target Price RM1.84

■ We view LSK as a proxy to the recovery in consumer spending, backed by: i)
higher mattress sales, ii) price hikes, and iii) higher economies of scale.
■ We expect LSK’s collaboration with Cuckoo Malaysia to propel its profitability
to new heights going forward, with more marketing activities expected.
■ LSK’s valuation is undemanding at 5.5x CY23 P/E, an 81.6% discount to our
discretionary consumer sector’s mean CY23 P/E. Reiterate Add.

Witnessing a rebound in local sales since 4Q21

Since the gradual lifting of lockdown measures starting Oct 21, LSK has been witnessing
a strong rebound in sales in the local market. This is in tandem with the reopening of its
retail outlets, as well as more large-scale furniture fairs and exhibitions being held. On top
of that, we gather that LSK has seen a surge in mattress sales in areas affected by the
recent floods. Supported by the price increases effective 1H21, we expect the higher sales
to translate into margin expansion for the company from 4Q21 onwards.

Sales of A-series mattress in 2021 affected by lockdowns

While LSK aimed to sell 12,000 A-series mattresses (sold under LSK‘s collaboration with
Cuckoo) in 2021F, sales likely fell short (estimated to reach only 7,000, which is in line with
our estimates) due to the impact of various lockdowns throughout 2021. Nevertheless, we
take comfort that sales in May 21 (prior to the implementation of a full movement control
order [FMCO] in Jun-Sep 2021) was an encouraging 1.5k units.

Still optimistic on prospects of collaboration with Cuckoo

We remain optimistic about LSK’s collaboration with Cuckoo International. With the lifting
of lockdown measures and supported by better consumer sentiment and more marketing
activities, LSK is confident of achieving sales of 20,000 units (+185% yoy) in FY22F. In our
view, the rental model (with low initial purchase cost) offered by Cuckoo-LSK when
purchasing A-series mattresses could also be an attractive proposition to buyers amid the
current subdued consumer sentiment. Note that LSK expects contributions from its
collaboration with Cuckoo to contribute at least 20% of its turnover from FY22F onwards.

Net cash position will support attractive dividend yields in FY23-24F

As at end-3Q21, LSK has a net cash position of RM5.6m. With no major capex planned in
FY22-23F (flat at RM3.5m for FY21-23F), we expect its robust balance sheet to support its
dividend payouts (45% for FY21-23F). With an expected rebound in earnings, mainly in
FY22-23F, this could translate into solid dividend yields of 2.9-8.3% for FY21-23F.

Reiterate our Add call

We make no changes to our FY22-24F EPS forecasts. We also keep our Add call and TP
of RM1.84, based on 13x CY23 P/E, in line with its 5-year mean. We continue to like LSK
for its: i) defensive business (resilient demand for beds); ii) attractive valuation (5.5x CY23F
P/E); and iii) strong fundamentals (high ROE and net cash position). Re-rating catalyst: a
spike in sales volume and higher-than-expected sales from its collaboration with Cuckoo.

CGSCIMB Research January 12, 2022

Stock

2022-02-11 12:50 | Report Abuse

Hugh expansion in Nilai, Kapar & Jv with Kulim in Johore.

Stock
Stock

2022-02-10 07:17 | Report Abuse

Taiwan’s Foxconn planning for 150,000 EVs by 2030 in Thailand joint venture
https://www.taiwannews.com.tw/en/news/4435031

Stock
Stock

2022-02-04 17:21 | Report Abuse

Chip giants are ramping up spending by the billions as semiconductor demand booms
https://www.cnbc.com/2022/02/04/tsmc-intel-ramp-up-spending-as-semiconductor-demand-booms.html

Stock
News & Blogs

2021-12-31 17:11 | Report Abuse

Mr Tan KW,

My Picks for 2022 (I am No. 11 for year 2019)

1) Atech 10 %
2) Dnex 25 %
3) Frontkn-Wb 10 %
4) Genetec 25 %
5) Jftech-Wa 10 %
6) Ktb 10 %
7) Rhonema-Wa 10 %

Thank you,
Rikki

Stock

2021-12-08 06:49 | Report Abuse

Apple shares rise as Morgan Stanley raises price target from $164 to $200
https://www.cnbc.com/2021/12/07/morgan-stanley-raises-apple-stock-price-target-to-200.html

Stock

2021-11-26 08:16 | Report Abuse

EPS 4.346m/223.05m = 2 cts. Hidden gem tech counter. PE 10 = 0.80, PE 15 = 1.20, PE 20 = 1.60

Stock

2021-11-17 09:05 | Report Abuse

Nich996 not to forget the JV with Kurim (M) Berhad would be completed in Q4 and more expansion incoming! hold tight :)
17/11/2021 7:29 AM

Thank you for highlighting

https://www.theedgemarkets.com/article/rhone-ma-diversify-dairy-operations-through-jv-kulim

Stock

2021-11-17 08:00 | Report Abuse

Prospects - Q3 Sep 2021 Report 16112021

The continued expansion of our capacity and operations through our future plans would provide a platform to grow and sustain our business. The Group will continue to focus on strengthening its production capabilities, product competitiveness and market position, while constantly seeking ways to mitigate the risks associated with its business. The Group will also continue to improve its internal controls and processes based on prudent management practices. In addition to improving on current operations, the Group is vigilant in identifying new business opportunities that has the potential for continuous growth and expansion.

In line with the projected growth of the Malaysian economy, the livestock industry is also anticipated to grow due to the corresponding growing Malaysian population resulting in the demand for meat as a source of protein to soar. The estimated increase in livestock in Malaysia is expected to result in correlating increase in demand for animal pharmaceutical and veterinary products, including animal feed to meet the rising needs. This is expected to augur well for the Group to ride on the growth trajectory in line with the government’s endeavour to develop a sustainable livestock industry in the country for national food security.

We are also anticipating growth in our dairy production business segment due to the projected uptrend in the local market. The production of milk in Malaysia was expected to increase in line with the government’s aim to increase the country’s fresh milk self-sufficiency level to 100% within five years and this will create abundant opportunities for the Group to capitalise on.

The Covid-19 pandemic that has been sweeping the globe in recent times has been anticipated to have a negative impact on the Malaysian macro-economy as well as on the economic welfare of its population. Notwithstanding these developments, the Group which is actively involved in the animal health and nutrition market, is within the ambit of the food industry’s supply chain and the Board is cautiously optimistic of the minimal impact that the pandemic will have on our operations.

Stock

2021-10-29 18:06 | Report Abuse

Budget 2022 - Under the free school meals programme, RM400mil has been allocated to provide free milk daily from local suppliers
https://klse.i3investor.com/blogs/savemalaysia/2021-10-29-story-h1592950394-Budget_2022_RM450mil_allocated_for_early_school_aid_to_three_million_st.jsp

News & Blogs

2020-12-31 17:34 | Report Abuse

Mr Tan KW,

My Stock Pick for Year 2021 ( I was No. 2 for Year 2017 & No. 11 for Year 2019 )

1) Jaks-Wc 30 %
2) Advcon 10 %
3) Camres 10 %
4) Focusp 10 %
5) Jftech 10 %
6) Lagenda-Wb 10 %
7) Ocb 10 %
8) Sasbadi 10 %

Thank you,
Rikki

Stock

2020-12-09 11:12 | Report Abuse

LBALUM's profits more than doubled compared to previous quarter, hence share price has been reacting prior to the release of result yesterday.

Given the same industry, ARANK is having a breakout ahead of their quarterly result this month, based on the momentum we expect further upside should be seen towards RM0.65-0.68. Support at RM0.585.

Current LBALUM's PE stood at ~18.8x, while ARANK is trading around 13.2x, implying upside potential of >30%.

Source: M+ Online, Bloomberg